|Mr. Kevin A. Richardson II||Chairman & CEO||277.46k||N/A||1968|
|Ms. Lisa E. Sundstrom||Chief Financial Officer||208.88k||N/A||1969|
|Mr. Peter Stegagno||Chief Operating Officer||215.14k||N/A||1960|
|Dr. Iulian Cioanta||Chief Science & Technology Officer||223.61k||N/A||1963|
|Mr. Shri P. Parikh||Pres of Healthcare Division||323.5k||N/A||1972|
SANUWAVE Health, Inc., a shock wave technology company, focuses on the development and commercialization of noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States, Europe, Canada, Asia, and the Asia Pacific. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device that has completed its Phase III clinical studies for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. It markets and sells its devices and accessories. SANUWAVE Health, Inc. was founded in 2005 and is headquartered in Suwanee, Georgia.
SANUWAVE Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.